Warfarin Pharmacogenomics in Diverse Populations

Pharmacotherapy

Volumn 37, Issue 9, 2017, Pages 1150-1163

  Kaye, Justin B ^a   Schultz, Lauren E ^a   Steiner, Heidi E ^a   Kittles, Rick A ^b   Cavallari, Larisa H ^c   Karnes, Jason H ^a,b,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

anticoagulation; diversity; pharmacogenomics; warfarin

Indexed keywords

CYTOCHROME P450 2C9; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; ANTICOAGULANT AGENT;

AFRICAN AMERICAN; ALASKA NATIVE; AMERICAN INDIAN; ASIAN; BLEEDING; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; ETHNIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; DRUG EFFECT; ETHNIC GROUP; GENETICS; PROCEDURES; TRENDS;

ANTICOAGULANTS; ETHNIC GROUPS; HUMANS; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 85029440591     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1982     Document Type: Review

References (80)

1. Aitken M, Kleinrock M. Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012. Parsippany, NJ: IMS Institute for Healthcare Informatics. 2013:1–50.
2. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med 2015;128(1300–5):e2.
3. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002–12.
4. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–37.
5. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239–45.
6. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689–96.
7. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin–nature or nurture? Clin Pharmacol Ther 2001;70:159–64.
8. PGKB PKI. U.S. Food and Drug Administration (FDA) label information for warfarin and CYP2C9, PROC, PROS1, VKORC1. 09-01-2016 label update 2016.
9. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326–31.
10. Verhoef TI, Redekop WK, Daly AK, van Schie RMF, de Boer A, Maitland-van der Zee A-H. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol 2014;77:626–41.
11. Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 2017;doi:10.1002/cpt.668 (Epub ahead of print).
12. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39:1008–12.
13. Fohner AE, Robinson R, Yracheta J, et al. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet Genomics 2015;25:343–53.
14. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115:3827–34.
15. Limdi NA, Brown TM, Yan Q, et al. Race influences warfarin dose changes associated with genetic factors. Blood 2015;126:539–45.
16. Perera MA, Cavallari LH, Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin Pharmacol Ther 2014;95:242–4.
17. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283–93.
18. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294–303.
19. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304–12.
20. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753–64.
21. Golwala H, Jackson LR, Simon DN, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from outcomes registry for better informed treatment for atrial fibrillation registry. Am Heart J 2016;174:29–36.
22. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309–15.
23. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99–111.
24. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23–34.
25. Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009;113:4977–9.
26. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010;87:445–51.
27. King CR, Deych E, Milligan P, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010;104:750–4.
28. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans. Pharmacogenomics 2012;13:1925–35.
29. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.
30. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e152S–84S.
31. French B, Wang L, Gage BF, Horenstein RB, Limdi NA, Kimmel SE. A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics 2016;26:445–52.
32. Yong C, Azarbal F, Abnousi F, et al. Racial differences in quality of anticoagulation therapy for atrial fibrillation (from the TREAT-AF Study). Am J Cardiol 2016;117:61–8.
33. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084–97.
34. Perera MA, Gamazon E, Cavallari LH, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011;89:408–15.
35. Alzubiedi S, Saleh MI. Pharmacogenetic-guided warfarin dosing algorithm in African–Americans. J Cardiovasc Pharmacol 2016;67:86–92.
36. Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J 2014;14:223–8.
37. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012;13:407–18.
38. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol 2013;75:334–46.
39. Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol 2012;8:563–76.
40. Cavallari LH, Perera M, Wadelius M, et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 2012;22:152–8.
41. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African–American individuals: a genome-wide association study. Lancet 2013;382:790–6.
42. Bosch LÁB. A proposal for an individualized pharmacogenetic-guided warfarin dosage regimen for puerto rican patients commencing anticoagulation therapy. J Pharmacogenomics Pharmacoproteomics 2014;5:T-001.
43. Duconge J, Ramos AS, Claudio-Campos K, et al. A novel admixture-based pharmacogenetic approach to refine warfarin dosing in Caribbean Hispanics. PLoS ONE 2016;11:e0145480.
44. Ramos AS, Seip RL, Rivera-Miranda G, et al. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics 2012;13:1937–50.
45. Santos PCJL, Marcatto LR, Duarte NE, et al. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics 2015;16:865–76.
46. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MAG. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 2011;46:147–50.
47. Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010;19:4735–44.
48. Liang R, Li L, Li C, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012;34:120–5.
49. Zeng WT, Xu Q, Li CH, et al. Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. Eur J Clin Pharmacol 2016;72:1327–34.
50. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African–Americans. Pharmacogenomics 2007;8:1535–44.
51. Botton MR, Bandinelli E, Rohde LEP, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011;72:442–50.
52. Lin M, Yu L, Qiu H, Wang Q, Zhang J, Song H. Verification of five pharmacogenomics-based warfarin administration models. Indian J Pharmacol 2016;48:258–63.
53. Cho S-M, Lee K-Y, Choi JR, Lee K-A. Development and comparison of warfarin dosing algorithms in stroke patients. Yonsei Med J 2016;57:635–40.
54. Zhao L, Chen C, Li B, et al. Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement. PLoS ONE 2014;9:e94573.
55. Lei X, Guo Y, Sun J, et al. Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients. Am J Hematol 2012;87:541–4.
56. Cho H-J, On Y-K, Bang OY, et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther 2011;33:1371–80.
57. Drozda K, Wong S, Patel SR, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics 2015;25:73–81.
58. Perini JA, Struchiner CJ, Silva-Assunção E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 2008;84:722–8.
59. Chen J, Shao L, Gong L, et al. A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. PLoS ONE 2014;9:e105250.
60. Jiang N-X, Ge J-W, Xian Y-Q, Huang S-Y, Li Y-S. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients. Biomed Rep 2016;4:453–8.
61. Krishna Kumar D, Shewade DG, Loriot M-A, et al. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol 2014;70:47–56.
62. Tan SL, Li Z, Song GB, et al. Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. Pharmazie 2012;67:930–7.
63. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015;25:33–41.
64. Price ET. Warfarin pharmacogenomics and African ancestry. Blood 2015;126:434–6.
65. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature 2016;538:161–4.
66. Kubo K, Ohara M, Tachikawa M, et al. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. Pharmacogenomics J 2016;doi:10.1038/tpj.2016.57 (Epub ahead of print).
67. Saleh MI, Alzubiedi S. Dosage individualization of warfarin using artificial neural networks. Mol Diagn Ther 2014;18:371–9.
68. Liu R, Li X, Zhang W, Zhou HH. Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse international warfarin pharmacogenetic consortium cohort database. PLoS ONE 2015;10:e0135784.
69. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651–81.
70. Karnes JH, Van Driest S, Bowton EA, et al. Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med 2014;6:125–35.
71. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625–9.
72. You JH. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother 2011;12:435–41.
73. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73–83.
74. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009;2:429–36.
75. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28:61–74.
76. You JH. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics 2015;16:1089–100.
77. Dahal K, Sharma SP, Fung E, et al. Meta-analysis of randomized controlled trials of genotype-guided vs standard dosing of warfarin. Chest 2015;148:701–10.
78. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009;10:1687–95.
79. Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS ONE 2016;11:e0146262.
80. Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2014;95:199–207.